Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Biotechnology

Healthcare
$247.77 +0.02%

+$0.05 today

Market cap
$15.90B
Beta
0.33
P/E (TTM)
476.3
EPS (TTM)
$0.48
52W Low $105.00High $243.32

Volume 0.72M

Average 0.92M

JAZZ Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Jazz Pharmaceuticals plcNASDAQ: JAZZ

Operating Income · Q3 FY2026 · quarter ended Sep 2026

Operating income turns negative

Q3 FY2026 operating income was -$413.4M, compared with $57.51M a year earlier. Trailing-twelve-month operating income was $957.8M.

Context

  • Operating income amounted to 5.3% of revenue in FY2025, down 12.4 pp from a year earlier.
  • Operating income increased in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 16 analysts of $1.49B (+561.9%) for the fiscal year ending Dec 2026, a step up from the -68.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$413.4M-266.6% QoQ
Last fiscal yearDec 2025
$224.42M-68.7% YoY
LTMSep 2026
$957.8M+293.9% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-818.8%-34.9%+784.0 pp
1 year-68.7%+561.9%+630.6 pp
3-year CAGR—+124.6%—
5-year CAGR+65.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
224.42M USD
Year-over-year change
-68.7%
4-year CAGR
+7.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How JAZZ compares with its peers on the latest reported figures

  • JAZZ's LTM Sep 2026 operating income of $957.8M is the 3rd highest of the 9 companies compared; the peer median is $211.76M.
  • Its year-over-year change of +293.9% is the 2nd highest of 8, against a peer median of +87.6%.
  • Operating income amounts to 20.3% of revenue for JAZZ, versus a peer median of 27.8%.
JAZZ Competitors Peer median
Operating Income for JAZZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$1.84B +89.2%+31.4%31.6%
GMABGenmab A/SLTM Jun 2026$1.33B —-41.6%32.3%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$957.8M +293.9%—20.3%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$881.2M +60.2%+35.5%23.8%
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$230.65M +4.0%+20.2%24.0%
TGTXTG Therapeutics, Inc.LTM Sep 2026$192.86M +87.6%—21.5%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$100.93M +394.5%+149.6%34.7%
LEGNLegend Biotech CorporationLTM Sep 2026$34.1M +117.9%—2.5%
MGNXMacroGenics, Inc.LTM Mar 2026-$63.66M +36.0%—40.5%
Peer median (excluding JAZZ) $211.76M+87.6%+31.4%27.8%

Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.09B3.66B3.83B4.07B4.27B
Cost of Revenue440.76M540.52M435.58M445.71M503.3M
Gross Profit2.65B3.12B3.4B3.62B3.76B
Gross Margin85.8%85.2%88.6%89.0%88.2%
Research & Development505.75M590.45M849.66M884M782.74M
Selling, General & Admin1.45B1.42B1.34B1.39B1.81B
Operating Expenses2.48B3.18B2.82B2.91B3.54B
Depreciation & Amortization552.48M629.47M638.7M660.07M696.3M
EBITDA1.03B1.47B1.45B1.52B262.76M
EBITDA Margin33.2%40.1%37.8%37.4%6.2%
Operating Income170.28M(65.53M)578.58M716.63M224.42M
Operating Margin5.5%-1.8%15.1%17.6%5.3%
Interest Income00000
Interest Expense278.77M288.24M289.44M238.1M195.05M
Other Income / Expenses(283.83M)(317.18M)(283.66M)(247.94M)(853.01M)
Income Before Tax(113.55M)(382.71M)294.92M468.69M(628.59M)
Pre-Tax Margin-3.7%-10.5%7.7%11.5%-14.7%
Income Tax Expense216.12M(158.65M)(119.91M)(91.43M)(272.44M)
Net Income(328.95M)(224.06M)414.83M560.12M(356.15M)
Net Margin-10.6%-6.1%10.8%13.8%-8.3%
EPS (Basic)(5.51)(3.58)6.559.06(5.84)
EPS (Diluted)(5.51)(3.58)6.108.65(5.84)
Weighted Avg Shares59.69M62.54M63.29M61.84M60.98M
Weighted Avg Shares (Diluted)59.69M62.54M72.07M66.01M60.98M

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Intrinsic Alpha fair value

Locked

Current Price

$247.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.